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T cells as mediators in renal ischemia/reperfusion injury. Inflam-
mation has been established to contribute substantially to the
pathogenesis of ischemia/reperfusion (I/R) with a central role
for particular cells, adhesion molecules, and cytokines. Until
recently, most of the research trying to unravel the pathogen-
esis of I/R injury has been focused on the role of neutrophils.
However, recent studies have brought evidence that T cells and
macrophages are also important leukocyte mediators of renal
and extrarenal (liver) I/R injury. In vivo depletion of CD4+ cells
but not CD8+ cells in wild-type mice was protective in I/R of
the kidney. A marked preservation of liver function was also
found after I/R in T-cell deficient athymic mice. Blocking the
B7/CD28 costimulatory pathway by CTLA-4 Ig (recombinant
fusion protein) ameliorated renal dysfunction and decreased
mononuclear cell infiltration in I/R of the kidney. B7-1 expres-
sion was found limited to the membrane of the endothelial
cells of the ascending vasa recta, resulting in trapping of CD28-
expressing CD4 T cells. This trapping of leukocytes results in
the upstream congestion in the ascending arterial vasa recta,
generating the since more than 150 years described medullary
vascular congestion of the kidney soon after ischemic injury.
It seems worthwhile to study a combination therapy using anti-
inflammatory/anti-adhesion molecules in the early phase of I/R.
Acute renal failure (ARF) is a common renal disease
affecting about 5% of all hospitalized patients. ARF still
carries a very high mortality of more than 50% and there
has been almost no significant change in mortality over
the last four decades [1, 2]. The kidney is highly vul-
nerable to the deleterious effects of renal hypoperfusion
(ischemia) and to many toxic substances, or a combina-
tion of both. Renal ischemia/reperfusion (I/R) injury is
the major cause of ARF in the native [3] as well as in the
transplanted kidney [4]. Although the renal functional
decline may be very pronounced, it is remarkable that the
acutely injured kidney has a striking regeneration capac-
ity. As opposed to chronic renal failure, in the majority
of cases of ARF the kidney will regain complete func-
tionality in the absence of interstitial inflammation and
fibrosis.
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There is no specific treatment for this devastating clin-
ical syndrome, reflecting, in part, the relatively poor un-
derstanding of the pathophysiology of this disease [5].
The pathogenesis of I/R injury is complex, but inflam-
mation is an established feature. Indeed, a manifest and
intriguing effect during acute tubular necrosis (ATN) and
repair is the prompt appearance, immediately following
injury, and disappearance of inflammatory cells when the
regeneration is complete. Both detrimental and regen-
erative potentials have been ascribed to these cells [6].
Although the literature on the possible role of these in-
terstitial leukocytes is abundant, their exact initiating and
resolving mechanisms and their effect on early and final
outcome of ARF are still unclear. Until recently, most of
the research unraveling the pathogenesis of I/R injury has
been focused on the role of the neutrophil [5]. However,
recent studies have brought evidence that T cells could
be also important leukocyte mediators of renal and ex-
trarenal (liver) I/R injury [7–10].
LEUKOCYTE ADHESION/INFILTRATION
AFTER I/R INJURY
Despite much attention to the role attributed to leuko-
cytes in I/R injury of different organs, the composition
and the kinetics of this infiltrate in relation to the evolu-
tion of the pathology is still not clearly defined. In the kid-
ney, polymorphonuclear cells (PMNs) recruited during
reperfusion have been considered as critical mediators
of the early parenchymal injury in ischemic ARF. How-
ever, clear evidence demonstrating that the number of
PMNs has a critical role on outcome of ARF is still
lacking [11]. On the other hand, the presence of mono-
cytes/macrophages and T cells in experimental models of
I/R injury seems to be consistent. Depending on the renal
insult, the kinetics of this mononuclear infiltrate (mono-
cytes/macrophages and T cells) may vary as well as the
participation of other leukocytes (B cells, PMNs, etc.). It
is remarkable that macrophages and T lymphocytes re-
main localized predominantly in the zone of most severe
injury, which is the outer stripe of the outer medulla [12].
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Tissue injury after ischemia is not only the consequence
of tissue hypoxia from interrupted blood supply but also
from the process of reperfusion leading to an active
inflammatory response, consisting in recruitment of pe-
ripheral leukocytes and in proliferation of resident in-
terstitial cells. This process is triggered by local injured
endothelial and parenchymal cells through the release of
cytokines, chemokines, and complement, initiating a se-
ries of coordinated steps of tethering, triggering, strong
adhesion, and transendothelial migration. Up-regulation
of local and systemic cytokines, like tumor necrosis factor-
a (TNF-a), interferon-c (INF-c), interleukin (IL)-1, IL-2,
and IL-8 [13], involved in macrophage and T-cell acti-
vation, provide a possible mechanism of up-regulation
of intercellular adhesion molecule-1 (ICAM-1) [14], and
others like E-selectin and P-selectin [15], in postischemic
tissue. I/R injury is associated with complement acti-
vation, and increased levels of lipid mediators, such as
leukotrienes and platelet activating factor (PAF), which
are chemotactic for neutrophils [16]. When the endothe-
lium becomes activated by cytokines (triggering), there
is rapid translocation of integrins from cytoplasmatic
granules to the plasma membrane of the endothelial cell.
Tethering interactions between leukocyte and endothe-
lial cells slows down the leukocyte, mediated by selectins
and their ligands. Firm adhesion between the endothe-
lium and the leukocyte takes place, mediated by integrins
and ICAMs. Adherent and activated leukocytes, among
them PMNs as prototype, release reactive oxygen species,
myeloperoxidase, proteases, elastases, leukotrienes, and
other enzymes that damage the ischemic tissue directly,
enhance additional inflammatory cell infiltration and in-
crease vasoconstriction [17]. Strong adhesion and subse-
quent transendothelial migration through the basement
membrane takes place preferentially at peculiar sites in
blood vessels, the postcapillary venules [18], mediated by
release of proteases, produced by the emigrating leuko-
cyte.
This leukocyte infiltrate, however, is a rather late phe-
nomenon, its manifestation occurs after the damage is
overt and at the time of regeneration. More recently, at-
tention has been focused on the earlier initial phase post-
I/R injury, which involves microvascular hemodynamic
changes. Interaction of leukocytes with the endothe-
lium, involving red blood cell sludging with platelets,
may cause capillary plugging, which can interfere with
the restitution of blood flow to areas of the kidney
upon reperfusion even though total renal blood flow has
been restored (“no-reflow phenomenon”) [19]. Blocking
leukocyte-endothelial interactions resulted in significant
protection from renal I/R injury in different experimental
models. Of these, interventions that block T-cell function
and interaction has yielded so many insights in the crucial
role of the T cell as key mediator in I/R injury that per-
haps time has come to put forward the concept of “I/R
injury as a T cell disease.”
T-CELL INFILTRATION 1 TO 14 DAYS AFTER I/R
INJURY (DURING REGENERATION)
A manifest effect during ATN and repair is the in-
creased presence of inflammatory cells and the occur-
rence of interstitial edema. A mixed mononuclear cell
(macrophage and CD4+ cell) infiltration of the kidney,
within a few days after I/R injury, was described after
45 minutes warm ischemia [7, 20] and after experimental
cold ischemia [21], but with limited information on the
different topographic localizations. In these and many
other studies no important neutrophilic infiltration was
mentioned, while others, using enzymatic tests and mem-
brane markers, describe mainly neutrophilic infiltration
[22, 23]. A very detailed identification and quantifica-
tion of the interstitial leukocytes in the rat kidney af-
ter I/R injury demonstrated a sequential accumulation
(after 5 to 10 days) of monocytes/macrophages and helper
T cells, a few suppressor/cytotoxic T cells but no B cells or
neutrophils [12]. The overt presence of this mononuclear
leukocyte infiltrate at the side of most injured tissue dur-
ing regeneration suggests a role in the repair process after
ARF. The macrophages in this mononuclear cell infiltrate
act as phagocytes, important scavengers of apoptotic cells
or necrotic debris [3]. Activated mononuclear cells can
produce various kinds of growth factors able to promote
epithelialization, angiogenesis, and extracellular matrix
turnover, necessary for wound repair [24].
This infiltration of neutrophils and macrophages is
clearly part of a nonspecific inflammatory reaction, the
presence however of T cells (and dendritic cells) within
these lesions questions their role in initiation, mainte-
nance, and possible amplification of the inflammatory re-
sponse. Whether or not the recruitment and activation of
these immunocompetent cells are mediated by antigen-
dependent or antigen-independent remains unanswered
until now. Nevertheless, the expression of major histo-
compatibility complex (MHC) class II antigens by the
injured tubular epithelium, picked up and presented by
recruited dendritic cells to autoreactive CD4+ T cells,
represent autoreactive cellular immunity important in the
discrimination between self and nonself [25]. Only when
ischemic damage is too severe, there is a progressive loss
of tolerance to parenchymal self, resulting in persistent
accumulation of immunocompetent cells in these areas
of active tubulointerstitial injury [26].
T CELLS IN THE INITIATION PHASE
OF REPERFUSION INJURY (<24 HOURS
POST-I/R INJURY)
After severe warm I/R injury of the rat kidney, a pro-
nounced ATN can be noticed after 24 hours in the absence
of a marked cellular infiltrate. In this very early, critical
period postischemia important myeloperoxidase (MPO)-
activity can be noticed, which most authors interpret as a
reflection of important PMN infiltration [14, 27]. PMNs
recruited during reperfusion have long been implicated
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as critical mediators of the early renal parenchymal in-
jury in ischemic ARF, supported by MPO assays but also
by other enzymatic criteria like chloroacetate esterase
[23, 28, 29] or labeling techniques (e.g., 111indium label-
ing [30]), all considered as specific for PMN infiltration.
Neutrophilic presence, however, investigated by others
using hematoxylin and eosin staining, revealed only a few
neutrophils in glomeruli, medullary rays and outer stripe
of the outer medulla [12, 31]. The so-called PMN-specific
staining techniques (MPO, chloroacetate esterase, etc.),
however, are not able to distinguish the difference be-
tween macrophages and PMNs [11]. The observation that
also monocytes/macrophages infiltrated the ischemic kid-
ney already during the first 24 hours, their number being
12 to 25 times higher than the present PMNs, contribute
to solve the controversy about the number PMNs in re-
nal I/R injury. Macrophages like PMNs are capable to
secrete a wide array of reactive oxygen species, nitric
oxide, MPO, and proinflammatory cytokines when ac-
tivated [32]. Hence, MPO content of postischemic tissue
reflects not only presence of PMNs but at least also of acti-
vated residential interstitial macrophages and freshly em-
igrated monocytes/macrophages in inflamed tissue. These
observations explain the conflicting results in the litera-
ture concerning the presence of PMNs in I/R injury. Using
routine hematoxylin and eosin stains, infiltration of the
renal parenchyma by PMNs seemed not a prominent fea-
ture of human postischemic or experimental ARF, while
in contrast, studies using the above mentioned so-called
specialized stains for PMNs suggest robust PMN recruit-
ment to ischemic kidney [3]. It is thus quite possible that
the neutrophil has been overestimated as sole pathophys-
iologic factor in renal I/R injury.
Indirect evidence for a critical role for T cells in ARF
came from blocking one of the costimulatory pathways
necessary for T-cell activation. Blocking the B7-CD28
costimulation pathway by CTLA4 Ig, a recombinant
fusion protein, containing the extracellular domain of
human CTLA4 (a homologue of CD28), resulting in T-
cell anergy, ameliorated renal dysfunction and decreased
mononuclear cell infiltration in a model of renal cold is-
chemia [7, 33]. A more direct proof of the role of T cells
in I/R injury was demonstrated in mouse liver I/R injury
where a marked preservation of liver function was found
in T-cell–deficient athymic mice [34]. Adoptive transfer
of wild-type T cells restored the injury. In vivo deple-
tion of CD4+ cells, but not CD8+ cells in wild-type mice
was also protective in this model [34]. In renal I/R in-
jury CD4/CD8 double knockout mice demonstrated sig-
nificant functional protection [8]. Especially the CD4+
subset was identified as the important T-cell subset that
mediated renal I/R injury [10]. T-cell–deficient (nu/nu)
mice were also protected from renal I/R injury, and T-cell
adoptive transfer into these mice reconstituted the injury
phenotype. Again CD4 knockout mice showed marked
protection from renal I/R injury compared to wild-type
mice, and adoptive transfer of wild-type CD4+ cells into
these CD4 knockout mice led to a worsening injury phe-
notype, demonstrating the importance of CD4+ cells in
renal I/R injury [10].
The question arises if lymphocytes and costimulation,
besides functioning in rodents, also play an important role
in the immediate response to renal I/R injury in the hu-
man situation. Mononuclear leukocytes, not neutrophils,
have been identified in the vasa recta of human kidney
biopsies of acute renal failure [35]. The involvement of
the B7-CD28 pathway in the human setting was identi-
fied using a mouse antihuman anti-B7-1 antibody (5B5,
Innogenetics) by an indirect immunohistochemical stain-
ing. B7-1 expression was found only at the level of the
endothelial cells of the ascending vasa recta at the inner
stripe of the outer medulla (Fig. 1) in postischemic human
kidney. These findings were the first report of the involve-
ment of B7-1 molecule, expressed de novo after ischemia
(within 1 hour), on endothelial cells of the ascending vasa
recta in postischemic human renal tissue [36].
POSSIBLE MECHANISMS OF T CELLS IN THE
PATHOPHYSIOLOGY OF I/R INJURY
The indirect and now direct evidence that T cells are
important early mediators of I/R injury, even in the ab-
sence of alloantigen, suggest a more important role in the
early inflammatory response than functioning exclusively
as part of the late adaptive immune response. More ar-
guments become available that in this first critical phase,
these activated inflammatory cells adhere to the vascular
endothelium and simply block or slow down the vascular
flow in the capillary network, and thereafter re-enter the
systemic circulation (“hit-and-run” phenomenon). In a
later phase, firm adhesion and diapedesis takes place, gen-
erating the well-known infiltration and proliferation ob-
served in many conditions (ischemia, HgCl2, obstruction,
etc.). Hence, the beneficial functional effect of antiadhe-
sion therapy with, for example, antibodies to ICAM-1
and leukocyte function associated molecule-1 (LFA-1),
seems to have its explanation early at the level of the
microcirculation and/or at the level of inflammatory cell
activation, but not necessary at the level of the intersti-
tial infiltrate, which becomes apparent only at the time
the functional recovery. More evidence appears that the
activation and adherence of the inflammatory cells very
early after I/R seems to be more important in exacer-
bating post-ischemic damage, than the phenomenon of
infiltration itself. This appealing paradigm needs further
investigation.
The protective effect of blocking T-cell costimulatory
activity in the absence of the immune stimulus pro-
vided by alloantigens suggests an early T-cell monocyte/
macrophage activation possibly at the leukocyte-
endothelial interactivation level. The question arises if
this activation mechanism is antigen-dependent or not.
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Fig. 1. Organization of vascular compart-
ment of the kidney. (A) The medulla is arte-
rial supplied from the efferent arterioles of the
juxtamedullary glomeruli, giving supply to the
descending arterial vasa recta, and further to
the ascending venous vasa recta, draining into
the arcuate veins. Abbreviations are: OSOM,
outer stripe of outer medulla; ISOM, inner
stripe of outer medulla; IM, inner medulla.
(B) Very strong expression of B7-1, 2 hours
after ischemia/reperfusion (I/R) injury of the
kidney, at the level of the ascending vasa recta.
(C) Detailed expression of B7-1, 2 hours af-
ter I/R injury of the rat kidney, at the level
of the ascending venous vasa recta. (D) De-
tailed expression of B7-1, 2 hours after I/R
injury of the human kidney, at the level of
the ascending venous vasa recta. (E) Trap-
ping of CD28-expressing T cells in the ascend-
ing vasa recta (HIS-17 staining). (F) Trapping
of monocytes/macrophages in the ascending
vasa recta (ED-1 staining). (G) This trapping
of leukocytes in the ascending vasa recta re-
sults in an upstream congestion at the ascend-
ing arterial vasa recta. This congestion, or no-
reflow, represents a well known phenomenon
in acute ischemic injury, exacerbating during
reperfusion the ischemic damage.
Indeed, endothelial cells can initiate both primary and
secondary responses and because of the ability of these
cells to provide costimulatory signals to circulating T cells
and other cells, they may serve as the initial antigen pre-
senting cell in the immune responses in peripheral tis-
sues [37]. The important role of CD28 and interferon-c
(IFN-c) in renal I/R injury was demonstrated by the ob-
servation that adoptive transfer of CD4+ cells, deficient
in CD28 and IFN-c, did not restore the renal I/R injury
phenotype in CD4+ knockout mice in contrast to the
wild-type CD4+ cells [10].
The underlying mechanisms by which CD4+ cells
might mediate renal I/R injury are not known. A cur-
rent paradigm is that CD4+ cells have two main func-
tional subsets, Th1 cells and Th2 cells. Besides having spe-
cific cytokine profiles and cellular responses, these CD4+
cell subsets can be differentiated by two distinct tran-
scriptional regulatory factors, STAT4 and STAT6. The
STAT4 pathway is activated mainly by IL-12 leading to
Th1 differentiation, whereas the STAT6 pathway is acti-
vated by IL-4 leading to Th2 differentiation. In renal I/R
injury, STAT6-deficient mice with a defective Th2 phe-
notype have enhanced renal I/R injury. STAT4-deficient
mice have only mildly improved function. Renal phago-
cyte infiltration and ICAM-1 up-regulation were similar
in STAT4−/−, STAT6−/−, and wild-type mice [38], sug-
gesting that the Th1/Th2 balance plays an important role
in the pathogenesis of I/R injury.
In contrast with several studies supporting the role
of T lymphocytes in I/R injury, mice deficient in
recombination-activating gene (RAG)-1, which have no
mature B or T lymphocytes and fail to produce either
immunoglobulins or T-cell receptor proteins, were not
protected from I/R injury [39]. However, these RAG-1
(−/−)–deficient mice still have full potential natural killer
cells CD28+ T lymphocytes, which still may interact with
B7-1 at the level of endothelial cells of the ascending vasa
recta, thus responsible for leukocyte trapping resulting in
vascular congestion and reperfusion-associated injury.
PERSPECTIVES
The importance of the inflammatory response in
ARF is also illustrated by the protective effect of anti-
inflammatory peptides like a-melanocyte-stimulating
hormone and osteogenic protein-1 [23]. These peptides
have broad anti-inflammatory effects acting on the pro-
duction of many chemoattractant cytokines and expres-
sion of different leukocyte adhesion molecules.
Considering the importance of the interstitial
macrophage and lymphocytes infiltration involved in
the progressive sclerotic renal changes after severe
I/R injury, intervention by nonnephrotoxic immuno-
suppressive drugs like mycophenolate mofetil (MMF),
by its specific antilymphocytic action, may represent
an attractive therapeutic option. Recent observation
confirmed the almost complete arrest of the CD4+ and
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CD8+ cell proliferation after I/R injury under MMF
treatment [40].
However, the recent insights in the pathophysiologic
role of T cells give thoughts that these interventions
are too late in the time frame after I/R injury. A much
more attractive and perhaps more efficient therapeutic
window occurs much more earlier, in the first minutes
to hours after the onset of reperfusion. Here could be
a role for CTLA4 Ig, anti-B7 (humanized) monoclonal
antibodies, antithymocyte globulin preparations (which
contain many antiadhesion molecules), and others, even
in combination therapy. Coadministration of an agonist
of A2A-adenosine receptors and a type IV phosphodi-
esterase (PDE4) inhibitor was more effective than either
agent alone in inhibiting neutrophil oxidative activity of
human neutrophils and in inhibiting I/R injury in mouse
kidneys [41]. It will be worthwhile to study combination
therapy of such compounds to produce greater tissue pro-
tection from I/R injury than either compound alone.
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Endothelial injury and dysfunction: Role in the extension phase
of acute renal failure. The pathophysiology of ischemic acute
renal failure (ARF) involves a complex interplay between re-
nal hemodynamics, tubular and endothelial cell injury, and in-
flammatory processes. A growing body of evidence supports
the contribution of altered renal vascular function, especially at
the microvascular level, in initiating and subsequently extend-
ing the initial tubular injury. The extension phase of ischemic
ARF involves continued reduction in renal perfusion, ongoing
hypoxia, and inflammatory processes that occur during reper-
fusion and contribute to continued tubular cell injury. Vascular
endothelial cell injury and dysfunction play a vital part in this ex-
tension phase. With injury, the endothelial cell loses its ability to
regulate vascular tone, perfusion, permeability and inflamma-
tion/adhesion. This loss of regulatory function has a detrimental
impact upon renal function. Vascular congestion, edema for-
mation, diminished blood flow, and infiltration of inflammatory
cells have been documented in the corticomedullary junction
of the kidney. However, linking their genesis to microvascu-
lar endothelial injury and dysfunction has been difficult. New
diagnostic and therapeutic approaches to ischemic ARF must
incorporate these finding to devise early recognition strategies
and therapeutic approaches.
The cellular and molecular events involved in ischemic
acute renal failure (ARF) have been identified and a
much more complete understanding of how these events
result in cellular and organ dysfunction has been estab-
lished. Growing evidence indicates renal vascular en-
dothelial injury and dysfunction play an important part
in initiating and extending renal tubular epithelial injury
and thus contribute to the ongoing pathogenesis of is-
chemic ARF. In fact, what is becoming rapidly appar-
ent is that the lack of adequate renal cortical-medullary
reperfusion may be more deleterious than the classical
“reperfusion injury” secondary to oxygen and nitroge-
nous free radical formation. Therefore, the purpose of
Key words: endothelium, acute renal failure, ischemia, kidney disease,
inflammation, coagulation, vascular.
this review is to summarize what is known about endothe-
lial injury/dysfunction during and following ischemia in
the kidney, and to place these data into a unifying hypoth-
esis regarding immediate and delayed epithelial cell in-
jury and organ dysfunction. Finally, how therapy of ARF
should take into account the pathophysiology of endothe-
lial dysfunction will be discussed.
VASCULAR ENDOTHELIUM AS AN ORGAN
The concept of the endothelium as an organ has be-
come widely appreciated [1] given the recent recognition
of the consequences of endothelial injury and dysfunc-
tion in a range of disease states such as sepsis, hemolytic
uremic syndrome/thrombotic thrombocytopenic purpura
(HUS/TTP), diabetes, and hypertension. The endothe-
lium regulates vascular permeability and modulates vaso-
motor, inflammatory, and hemostatic responses. Impair-
ment of these vital endothelial cell functions during and
following renal ischemia can contribute to the impair-
ment of renal perfusion, continued renal hypoxia, and
the subsequent epithelial cell injury and diminution in
glomerular filtration rate (GFR) that are the hallmarks
of ARF. Endothelial cells in different vascular beds have
different characteristics [2]. Therefore, as the environ-
ment within the kidney changes dramatically from the
outer cortex to the medullary region, endothelial cells
may differ considerably within the kidney from region to
region.
EXTENSION PHASE OF ARF
The extension phase of ischemic ARF is ushered in
by two major events: (1) continued hypoxia following
the initial ischemic event and (2) an inflammatory re-
sponse [3]. Both events are more pronounced in the cor-
ticomedullary junction (CMJ), or outer medullary region,
of the kidney. Documentation of severely reduced blood
flow, stasis, and accumulation of red blood cells and white
